JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: Nullizygosity for the JAK2 46/1 haplotype is associated with inferior survival

A. Tefferi, T. L. Lasho, M. M. Patnaik, C. M. Finke, K. Hussein, W. J. Hogan, M. A. Elliott, M. R. Litzow, C. A. Hanson, A. Pardanani

Research output: Contribution to journalArticle

80 Scopus citations


A common JAK2 germline haplotype (46/1) has been associated with JAK2V617F (VF)-positive myeloproliferative neoplasms. The rs12343867 SNP (C/T) tags this haplotype. A total of 130 patients (77 VF-positive) with primary myelofibrosis (PMF) were analyzed for this informative SNP, using bone marrow-derived DNA. The observed 46/1 C allele frequencies in VF-positive (50%) and VF-negative (36%) patients were both significantly higher than expected in population controls (P0.01). Genotype distributions in VF-positive/VF-negative patients were CC 31%/9%, CT 38%/53% and TT 31%/38% (P0.01). CC genotype/C-allele frequencies in patients with 20% VF mutation burden (12%/37%) were similar (P0.95) to those seen in VF-negative patients (9%/36%), but were significantly lower (P0.01) than those seen in the presence of 50% mutation burden (67%/71%). The rs12343867 genotype did not correlate with the International Prognostic Scoring System (IPSS) score or karyotype. Unexpectedly, the TT genotype was associated with shortened survival (P0.01), which was not accounted for by IPSS score or VF allele burden. We conclude that JAK2 germline genetic variation affects disease susceptibility, and possibly survival, in PMF, regardless of VF mutational status. Allelic distortion from acquired uniparental disomy contributes to the appearance of a more pronounced effect on disease susceptibility in VF-positive patients, when studying clonally affected tissue.

Original languageEnglish (US)
Pages (from-to)105-109
Number of pages5
Issue number1
StatePublished - Jan 2010



  • Haplotype
  • JAK2
  • Myelofibrosis
  • Prognosis
  • SNP
  • V617F

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this